Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES001 for Prevention of Breast Cancer Therapy-Related Cardiotoxicity
ChiCTR2200056796Phase 2Recruiting
- Sponsor
- Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
- Start
- Mar 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer and Cardiotoxicity comparing ES001 with Placebo (2 arms). Primary endpoints: Left ventricular ejection fraction, Troponin I (TnI) and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
ES001
03
Conditions
breast cancerCardiotoxicity
Beyond the preview
Go deeper on ChiCTR2200056796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056796.